RECOMBINANT HUMANIZED ANTI-185HER2 MONOCLONAL ANTIBODY IN BREAST CANCER

用于乳腺癌的重组人源化抗 185HER2 单克隆抗体

• 批准号: 6245714
• 负责人: BARRY LEMBERSKY
• 金额: $ 1.76万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-18 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6245714
• 关键词: breast neoplasms; clinical research; clinical trials; human subject; human therapy evaluation; monoclonal antibody; neoplasm /cancer immunotherapy; recombinant proteins

The objective of this study is to provide an optional extension period of rhuMAb HER2 therapy to those patients whose metastatic breast cancer progressed during treatment on Protocol HO648g. It is anticipated that one patient will enter the study at Univ. Pittsburgh Cancer Institute at this time & 450 patients worldwide This is an open-label extension study of patients enrolled in protocol HO648g who developed progressive disease.

这项研究的目的是提供一个可选的延长期 大黄单抗HER2治疗转移性乳腺癌 在HO648G方案治疗期间取得进展。预计 一名患者将进入大学的研究。匹兹堡癌症研究所 目前全球有450名患者，这是一个开放标签的扩展 纳入HO648G方案的进展性患者的研究 疾病。